Eledon Pharmaceuticals Inc Stock News

Tegoprubart used as a key component of immunosuppression regimen in the second transplant of a genetically modified pig kidney into a human conducted at Massachusetts General Hospital Announced positive initial data from first three subjects with type 1 diabetes treated with tegoprubart as part of immunosuppression regimen following islet transplantation in investigator-initiated trial at UChic...

IRVINE, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that Steve Perrin, Ph.D.

Eledon Announces Tegoprubart Use as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human

IRVINE, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that David-Alexandre C.

Eledon Pharmaceuticals' Tegoprubart, a second-gen anti-CD40L antibody, shows promise in preventing organ rejection without thromboembolic risks, addressing unmet needs in kidney and islet cell transplantation. Early trials indicate Tegoprubart's safety and efficacy, with no major side effects and better kidney function compared to current standards like tacrolimus. Eledon has a market cap of $2...

Completed enrollment in Phase 2 BESTOW trial assessing tegoprubart in kidney transplantation four months ahead of schedule; on track to report topline results in fourth quarter of 2025 Presented updated data on 13 participants from ongoing Phase 1b trial that continue to support safety and tolerability of tegoprubart for prevention of organ rejection in kidney transplantation Announced positive...

Completed enrollment of Phase 2 BESTOW trial of tegoprubart in kidney transplantation four months ahead of schedule; on track to report topline results in fourth quarter of 2025 Announced positive initial data from first three subjects with type 1 diabetes treated with tegoprubart as part of immunosuppression regimen following islet transplantation in investigator-initiated trial at UChicago Me...

Positive phase 1b biomarker and eGFR data achieved from phase 1b study using tegoprubart for prevention of organ rejection in kidney transplant patients. Top-line data from the phase 2 BESTOW study, using tegoprubart for prevention of organ rejection in kidney transplant patients, expected in Q4 of 2025. The organ transplant immunosuppressant drugs market is expected to reach $6.4 billion by 2030.